Napo appoints Dennis Fenton to board
This article was originally published in Scrip
The US based pharma company Napo Pharmaceuticals has appointed Dr Dennis Fenton to its board of directors. He has more than30 years' experience in the pharma and biotech industries, including 25 years at Amgen , where he served in various roles in sales and marketing and R&D, and as executive vice-president. Dr Fenton is currently a director of several life science companies, including Xenoport, Amira Pharmaceuticals, Genelux and Kythera Biopharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.